Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis.

Slides:

Advertisements

Similar presentations

Dimethyl Fumarate and Peginterferon b-1a: New Insights Into the Pivotal Trials Pavan Bhargava, MD Johns Hopkins University School of Medicine, Baltimore,

Advertisements

C1q g/L C2 g/L C3 g/L C4 g/L A. B. C.D. E. Supplementary Figure 1 - Middleton et al. NR Supplementary Figure 1. Complement concentrations in CLL patient.

IgG IEF Diagnosing Multiple Sclerosis. Multiple Sclerosis CNS disorder Scar formation on outside of nerve cells of brain and spinal cord Inflammation.

Rituximab (RITUXAN) & Multiple Sclerosis

Original Article B-Cell Depletion with Rituximab in Relapsing- Remitting Multiple Sclerosis Stephen L. Hauser, M.D., Emmanuelle Waubant, M.D., Ph.D., Douglas.

 Evaluation of interaction between Vitamin D 3 and neural stem cell proliferation and differentiation in to oligodendrocyte as the myelinating cell 

Multiple sclerosis Pathology. Key principles Myelin function The differences between CNS and PNS Myelin Primary Demyelinating disease classification Multiple.

By Matthew Sampson. Overview What is it? Previous Treatments Monoclonal Antibodies Chimeric Molecules Oral Therapies Hematopoietic Stem Cells Future.

Multiple Sclerosis (MS) By: Morgan Farr Biology 1010.

Multiple Sclerosis Rohith M. Reddy. Multiple sclerosis (MS) involves an immune-mediated process in which an abnormal response of the body’s immune system.

Multiple Sclerosis Alan Chen 4/1/14. General Information Other names: disseminated sclerosis or encephalomyelitis disseminata Inflammatory disease that.

© 2014 Direct One Communications, Inc. All rights reserved. 1 A New Era of Therapy in Multiple Sclerosis: Balancing the Options and Challenges Ahead Jennifer.

Genetic Variation Influences Glutamate Concentrations in Brains of Patients with Multiple Sclerosis Robby Bonanno.

Sagittal FLAIR images - Stable nonenhancing hyperintensities within the pericallosal white matter and bilateral centrum semiovale, consistent with known.

Teaching NeuroImages: A 38-year-old woman with chronic progressive dysarthria, and gait disturbance. by Keon-Joo Lee, Jangsup Moon, Soon-Tae Lee © 2014.

Neuroplasticity and Rehabilitation Strategies Robert K. Shin M.D. VA MS Center of Excellence Assistant Professor Departments of Neurology and Ophthalmology.

AUTOIMMUNITY. Self/Non-self Discrimination Autoimmunity is a problem of self/non-self discrimination.

EXEMPLAR OF MULTIPLE SCLEROSIS INTRODUCTION AND ASSESSMENT.

Pathology and Pathogenesis of Multiple Sclerosis

Dennis Bourdette, MD VA MS Center of Excellence-West and

Genes and Chips. Genes….  The proper and harmonious expression of a large number of genes is a critical component of normal growth and development and.

R HEUMATOID F ACTOR ( RF ). Rheumatoid arthritis is a chronic inflammatory disorder that affects all joints either in hands or feet and other areas of.

AUTOIMMUNITY. Autoimmunity Breaking of self tolerance Both B and T cells may be involved (however, most are antibody mediated)

PRIMARY DISEASES OF MYELIN. Acquired forms - Characterized by preferential damage to previously normal myelin with relative preservation of axons and.

STUDY ON THE LEVELS OF TAU AND β-AMYLOID IN CSF OF PATIENTS WITH MULTIPLE SCLEROSIS Levente Szalárdy MD Department of Neurology University of Szeged Hungary.

Multiple Sclerosis. What is MS? This is a chronic and often disabling disease in which the body’s immune system (t-cells) attacks the central nervous.

The Major Histocompatibility Complex: Class II Abbey Jones.

Date of download: 6/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Quantification and Functional Characterization of.

Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease C Bjartmar, J.R Wujek, B.D Trapp Journal of.

Harry Irving, Hung Jiew Lee, John Parratt

Laurence H. Beck, Jr. , M. D. , Ph. D. , Ramon G. B. Bonegio, M. D

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

Multiple sclerosis Pathology.

Active Transport Notes

Figure Model contrasting the potential role of antibodies to myelin oligodendrocyte glycoprotein (MOG) or aquaporin-4 (AQP4) in opticospinal inflammationMOG-specific.

by Clemens B. Caspar, Shoshana Levy, and Ronald Levy

Figure 3 Antibodies to MOG using different secondary antibodies: Anti-human IgG (H + L), IgG1, or IgM(A) Comparison of binding to full-length myelin oligodendrocyte.

Discussion and Concluding Remarks

Volume 20, Issue 1, Pages (February 2013)

Nat. Rev. Neurol. doi: /nrneurol

Pediatric Multiple Sclerosis: The Dawn of a New Era?

Figure 3 Pathological activation of complement

Figure 1 Biomarkers associated with different clinical phases in MS

Figure 2 Brain biopsy Brain biopsy (A) Double staining with anti-aquaporin-4 (AQP4) antibody (dark green) and Luxol fast blue (blue) is shown. Loss of.

Figure Nuclear Nrf2 expression after fumarate therapy A new left occipital fluid-attenuated inversion recovery hyperintense (A), T1 hypointense (B), and.

Figure 2 Elevated antibody reactivities against myelin and Epstein-Barr virus (EBV) peptides in relapsing-remitting multiple sclerosis (RRMS) and higher.

Figure 5 Increased frequency of parenchymal CD138- and LMP-1–positive cells in MS Increased frequency of parenchymal CD138- and LMP-1–positive cells in.

Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)

Figure 4 Neuropathology of MOG and AQP4 antibody–associated demyelinating lesions in the brain The biopsy specimen revealed a small actively demyelinating.

Figure 2 Overview of the patient's history and immunofluorescence pattern of patient CSF IgG Overview of the patient's history and immunofluorescence pattern.

Hashimoto’s Encephalitis

Figure 4 Pattern of relapse in patients with MOG-Ab Five myelin oligodendrocyte glycoprotein antibody (MOG-Ab)–positive patients experienced a relapse,

A Curious Case of NMO Transverse Myelitis – Mystery Solved. Anna M

Episodic Neurological Channelopathies

Figure 4 Confirmatory cohorts to assess MOG-IgG1 assay(A) All 81 aquaporin-4 (AQP4)- seropositive patients (blue) from the Oxford National neuromyelitis.

Figure 7 VEGF as a mediator of neuroinflammatory disease

Autoimmunity Semester : III Course Title : Immunology Unit : III

Figure 4 Autopsy immunochemistry results

Figure 1 Anti-Epstein-Barr virus nuclear antigen-1 IgG quartile antibody status differences in MRI measures Anti-Epstein-Barr virus nuclear antigen-1 IgG.

Figure Overview of patients with demyelinating diseases, presence of clinical symptoms frequently associated with NMDAR encephalitis, and antibody status.

Figure 1 Levels of miR-150 are elevated in patients with multiple sclerosis (MS) and patients with clinically isolated syndrome (CIS) who convert to MS.

Figure 2. Detection of KIR4.1 autoantibodies using LIPS

Figure MRI brain comparison prior and after treatment and brain biopsy findings MRI brain comparison prior and after treatment and brain biopsy findings.

Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.

Mechanism of diminished NaCl and Mg2+ reabsorption in EAST/SeSAME syndrome. Mechanism of diminished NaCl and Mg2+reabsorption in EAST/SeSAME syndrome.

Peripheral surgery regulates expression of astrocytic markers.

Disease of the Central Nervous System By Eric Nauman

Figure 4 C5B3 decreased NMOSD mouse model lesions in vivo

Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis The rate.

Presentation transcript:

Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis

KIR4.1 – Possible Relevance to MS KIR4.1 expression –An ATP-sensitive inward rectifying potassium channel sub-unit –Critical to the development of oligodendrocytes and myelination Involved in the maintenance of the electro-chemical gradient across the cell membrane of perisynaptic astrocytes KIR4.1 expression –An ATP-sensitive inward rectifying potassium channel sub-unit –Critical to the development of oligodendrocytes and myelination Involved in the maintenance of the electro-chemical gradient across the cell membrane of perisynaptic astrocytes

KIR4.1 – Possible Relevance to MS Possible interaction between KIR4.1 and AQP4 at perivascular astrocyte processes that regulates water homeostasis In humans, mutations in the gene encoding KIR4.1 associated with the development of EAST or SeSAME syndrome (characterized by epilepsy, ataxia, tubulopathy, and sensorineural deafness) Possible interaction between KIR4.1 and AQP4 at perivascular astrocyte processes that regulates water homeostasis In humans, mutations in the gene encoding KIR4.1 associated with the development of EAST or SeSAME syndrome (characterized by epilepsy, ataxia, tubulopathy, and sensorineural deafness)

Study Design Objective: To identify/characterize serum IgG specific to MS MS/CIS patients (n=397) –MS patients diagnosed according to the 2005 McDonald criteria –CIS patients had > 1 episode compatible with MS relapse and >2 lesions on MRI, oligoclonal bands in the cerebrospinal fluid, or both 2 control groups (n = 388) –Patients with other neurologic diseases (n=329) –Age-matched healthy individuals (n=59) Objective: To identify/characterize serum IgG specific to MS MS/CIS patients (n=397) –MS patients diagnosed according to the 2005 McDonald criteria –CIS patients had > 1 episode compatible with MS relapse and >2 lesions on MRI, oligoclonal bands in the cerebrospinal fluid, or both 2 control groups (n = 388) –Patients with other neurologic diseases (n=329) –Age-matched healthy individuals (n=59) Srivastava R, et al. N Engl J Med. 201;367:

Results Specificity of Anti-KIR4.1 Antibodies for MS Serum levels of anti-KIR4.1 antibodies significantly higher in patients with MS (46.9%) than in patients with other neurologic diseases (0.9%) and in healthy individuals (0%) (P<.001 for both comparisons) No significant differences in anti-KIR4.1 antibodies among patients with CIS, RRMS, and progressive MS Serum levels of anti-KIR4.1 antibodies significantly higher in patients with MS (46.9%) than in patients with other neurologic diseases (0.9%) and in healthy individuals (0%) (P<.001 for both comparisons) No significant differences in anti-KIR4.1 antibodies among patients with CIS, RRMS, and progressive MS Srivastava R, et al. N Engl J Med. 201;367:

Results Specificity of Anti-KIR4.1 Antibodies for MS PBS or serum-depleted of anti-KIR4.1 antibodies injected into the cisternae magnae resulted in a normal pattern of glial fibrillary acidic protein (Gfap) and KIR4.1 expression, with KIR4.1 expressed in astrocytes and oligodendrocytes Injections of KIR4.1-reactive serum IgG resulted in altered Gfap expression, loss of KIR4.1 expression (particularly in the area of the subarachnoid space), and deposits of C9neo (a marker of complement activation) in regions of KIR4.1 depletion PBS or serum-depleted of anti-KIR4.1 antibodies injected into the cisternae magnae resulted in a normal pattern of glial fibrillary acidic protein (Gfap) and KIR4.1 expression, with KIR4.1 expressed in astrocytes and oligodendrocytes Injections of KIR4.1-reactive serum IgG resulted in altered Gfap expression, loss of KIR4.1 expression (particularly in the area of the subarachnoid space), and deposits of C9neo (a marker of complement activation) in regions of KIR4.1 depletion Srivastava R, et al. N Engl J Med. 201;367:

Conclusions Anti-KIR4.1 antibodies exist in some patients with MS These antibodies react with KIR4.1 protein expressed on glial cells and may induce structural damage to glial cells Anti-KIR4.1 antibodies may contribute to the development of MS by –Depleting KIR4.1 on glial cells and altering expression of Gfap in astrocytes –Inducing antibody-dependent cell-mediated cytotoxcitiy –Interfering with the channel function of KIR4.1, negatively effecting potassium buffering and neurotransmitter homeostasis Anti-KIR4.1 antibodies exist in some patients with MS These antibodies react with KIR4.1 protein expressed on glial cells and may induce structural damage to glial cells Anti-KIR4.1 antibodies may contribute to the development of MS by –Depleting KIR4.1 on glial cells and altering expression of Gfap in astrocytes –Inducing antibody-dependent cell-mediated cytotoxcitiy –Interfering with the channel function of KIR4.1, negatively effecting potassium buffering and neurotransmitter homeostasis Srivastava R, et al. N Engl J Med. 201;367:

Conclusions Perhaps the discovery of these autoantibodies in sub-groups of MS patients will assist in defining their prognosis and perhaps their response to treatment This study represents a break-through by considering a broader set of autoantibodies beyond those against myelin and EAE, and looking for new autoantibody reactivity Perhaps the discovery of these autoantibodies in sub-groups of MS patients will assist in defining their prognosis and perhaps their response to treatment This study represents a break-through by considering a broader set of autoantibodies beyond those against myelin and EAE, and looking for new autoantibody reactivity Abbreviations: EAE, experimental autoimmune encephalitis Srivastava R, et al. N Engl J Med. 201;367:

Conclusions Since only 47% of MS patients have serum anti-KIR4.1 antibodies, this provides a basis for identifying other targets of the immune response in MS and assessing the impact of these reactivities on treatment and disease prognosis Abbreviations: EAE, experimental autoimmune encephalitis Srivastava R, et al. N Engl J Med. 201;367: